Thioctic Acid (CID 6112) - BioAssay Data Summary for Compound
.
BioActivity Outcomes:
Active(6)
 
 
Inactive(153)
 
 
Inconclusive(20)
 
 
Unspecified(224)
 
 
Top Targets:
7TM GPCR Srx(16)
 
 
 
7TM GPCR Srsx(13)
 
 
 
 
p450(8)
 
 
Esterase lipa..(7)
 
 
 
HELICc(6)
 
 
 
BioAssay Types:
Confirmatory(142)
 
 
 
 
Literature(113)
 
 
 
 
 
Screening(13)
 
 
Summary(1)
 
 
BioActivity Types:
Potency(142)
 
 
 
 
IC50(132)
 
 
 
Kd(3)
 
 
EC50(2)
 
 
SAR
Target summary
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 379    Data Row: 403   Total Pages: 9   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103372397]
IC50 0.001Inhibition of human AchE [AID314091, Type: Literature]Acetylcholinesterase [gi:113037]
View
2
[SID103372397]
IC50 1.95Antioxidant activity assessed as hypochlorous acid scavenging activity by fluorescent rhodamine formation assay [AID453279, Type: Literature]
View
3
[SID103372397]
IC50 2.4Hypochlorous acid scavenging activity assessed as inhibition of DHR oxidation [AID289322, Type: Literature]
View
4
[SID103372397]
IC50 11Antioxidant activity assessed as hydroxyl radical scavenging activity [AID347225, Type: Literature]
View
5
[SID103372397]
IC50 19.6Neuroprotective effect was measured by its ability to protect mouse hippocampal neuronal HT-22 cell lines from oxidative stress caused by glutamate [AID84280, Type: Literature]
View
6
[SID103372397]
 Radical reducing potency by ABTS cation radical reduction assay per 30 mins at 1 umol/mL [AID264481, Type: Literature]
View
7
[SID103372397]
Kd 10Blocking activity was assessed by antagonism of (-)-phenylephrine induced contraction of rat spleen (alpha1B adrenoceptor) [AID239871, Type: Literature]
View
8
[SID103372397]
Kd 10Blocking activity was assessed by antagonism of (-)-noradrenaline induced contraction of rat thoracic aorta (Alpha-1D adrenoceptor) [AID239872, Type: Literature]
View
9
[SID103372397]
Kd 10Blocking activity was assessed by antagonism of (-)-noradrenaline induced contraction of rat prostatic vas deferens (alpha1A adrenoceptor) [AID239873, Type: Literature]
View
10
[SID103372397]
IC50 54.86Antioxidant activity against formation of ROS was determined in t-BuOOH treated LNCaP cells after 24 hr of incubation with compounds (1-100 uM) [AID248861, Type: Literature]
View
11
[SID103372397]
EC50 121.6Ability for prevention of GSH depletion was measured in mouse [AID127631, Type: Literature]
View
12
[SID103372397]
EC50 250Induction of apoptosis in human HT-29 cells [AID481542, Type: Literature]
View
13
[SID103372397]
IC50 400Evaluated for the interaction with 0.2 mM of the stable free radical DPPH. [AID197086, Type: Literature]
View
14
[SID103372397]
IC50 1000Inhibition of in vitro peroxidation (LP) of rat Hepatic microsomal membrane lipid [AID197084, Type: Literature]
View
15
[SID103372397]
IC50 1000Inhibition of human serum recombinant AChE after 20 mins using acetylthiocholine iodide as a substrate by Ellman's assay [AID625546, Type: Literature]Acetylcholinesterase [gi:113037]
View
16
[SID103372397]
IC50 1000Inhibitory concentration against human recombinant acetylcholinesterase [AID241200, Type: Literature]Acetylcholinesterase [gi:113037]
View
17
[SID103372397]
IC50 1000Inhibitory concentration against human recombinant butyrylcholinesterase [AID241230, Type: Literature]Cholinesterase [gi:116353]
View
18
[SID103372397]
IC50 1000Inhibition of human serum recombinant BChE after 20 mins using butyrylthiocholine iodide as a substrate by Ellman's assay [AID625547, Type: Literature]Cholinesterase [gi:116353]
View
19
[SID103372397]
IC50 DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin) [AID625213, Type: other]B2 bradykinin receptor [gi:2506481]
View
20
[SID103372397]
IC50 DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin) [AID625213, Type: other]B2 bradykinin receptor [gi:2506481]
View
21
[SID103372397]
IC50 DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr) [AID625233, Type: other]Vasopressin V1a receptor [gi:586197]
View
22
[SID103372397]
IC50 DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr) [AID625233, Type: other]Vasopressin V1a receptor [gi:586197]
View
23
[SID103372397]
IC50 DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr) [AID625233, Type: other]Vasopressin V1a receptor [gi:586197]
View
24
[SID103372397]
IC50 DRUGMATRIX: Vascular Endothelinal Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF) [AID625231, Type: other]Vascular endothelial growth factor receptor 1 [gi:143811474]
View
25
[SID103372397]
IC50 DRUGMATRIX: Vascular Endothelinal Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF) [AID625231, Type: other]Vascular endothelial growth factor receptor 1 [gi:143811474]
View
26
[SID103372397]
IC50 DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) [AID625253, Type: other]D(2) dopamine receptor [gi:118206]
View
27
[SID103372397]
IC50 DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) [AID625253, Type: other]D(2) dopamine receptor [gi:118206]
View
28
[SID103372397]
IC50 DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) [AID625253, Type: other]D(2) dopamine receptor [gi:118206]
View
29
[SID103372397]
IC50 DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) [AID625253, Type: other]D(2) dopamine receptor [gi:118206]
View
30
[SID103372397]
IC50 DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) [AID625253, Type: other]D(2) dopamine receptor [gi:118206]
View
31
[SID103372397]
IC50 DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) [AID625254, Type: other]D(3) dopamine receptor [gi:1169206]
View
32
[SID103372397]
IC50 DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) [AID625254, Type: other]D(3) dopamine receptor [gi:1169206]
View
33
[SID103372397]
IC50 DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) [AID625254, Type: other]D(3) dopamine receptor [gi:1169206]
View
34
[SID103372397]
IC50 DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) [AID625254, Type: other]D(3) dopamine receptor [gi:1169206]
View
35
[SID103372397]
IC50 DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone) [AID625255, Type: other]D(4) dopamine receptor [gi:1345939]
View
36
[SID103372397]
IC50 DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone) [AID625255, Type: other]D(4) dopamine receptor [gi:1345939]
View
37
[SID103372397]
IC50 DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone) [AID625255, Type: other]D(4) dopamine receptor [gi:1345939]
View
38
[SID103372397]
IC50 DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1) [AID625257, Type: other]Endothelin-1 receptor [gi:119606]
View
39
[SID103372397]
IC50 DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1) [AID625257, Type: other]Endothelin-1 receptor [gi:119606]
View
40
[SID103372397]
IC50 DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr)) [AID625184, Type: other]Epidermal growth factor receptor [gi:2811086]
View
41
[SID103372397]
IC50 DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr)) [AID625184, Type: other]Epidermal growth factor receptor [gi:2811086]
View
42
[SID103372397]
IC50 DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr)) [AID625184, Type: other]Epidermal growth factor receptor [gi:2811086]
View
43
[SID103372397]
 DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA) [AID625176, Type: other]Neutrophil elastase [gi:119292]
View
44
[SID103372397]
IC50 DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr)) [AID625186, Type: other]Receptor tyrosine-protein kinase erbB-2 [gi:119533]
View
45
[SID103372397]
IC50 DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr)) [AID625186, Type: other]Receptor tyrosine-protein kinase erbB-2 [gi:119533]
View
46
[SID103372397]
IC50 DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) [AID625258, Type: other]Estrogen receptor [gi:544257]
View
47
[SID103372397]
IC50 DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) [AID625258, Type: other]Estrogen receptor [gi:544257]
View
48
[SID103372397]
IC50 DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) [AID625258, Type: other]Estrogen receptor [gi:544257]
View
49
[SID103372397]
IC50 DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) [AID625258, Type: other]Estrogen receptor [gi:544257]
View
50
[SID103372397]
IC50 DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr)) [AID625185, Type: other]Tyrosine-protein kinase Fyn [gi:125370]
View